Recent

% | $
Quotes you view appear here for quick access.

Illumina Inc. Message Board

gadzillionman 134 posts  |  Last Activity: 10 hours ago Member since: Feb 19, 2004
  • Name and Address of Reporting
    Person *
    PAULSON & CO. INC.
    2. Date of Event Requiring
    Statement
    (Month/Day/Year)
    05/04/2016
    3. Issuer Name and Ticker or Trading Symbol
    SYNERGY PHARMACEUTICALS, INC. [SGYP]
    (Last) (First) (Middle)
    1251 AVENUE OF THE
    AMERICAS
    4. Relationship of Reporting
    Person(s) to Issuer
    (Check all applicable)
    _____ Director __X__ 10% Owner
    _____ Officer (give
    title below)
    _____ Other (specify
    below)
    5. If Amendment, Date Original
    Filed(Month/Day/Year)
    (Street)
    NEW YORK, NY 10020
    6. Individual or Joint/Group
    Filing(Check Applicable Line)
    _X_ Form filed by One Reporting Person
    ___ Form filed by More than One Reporting
    Person
    (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned
    1.Title of Security
    (Instr. 4)
    2. Amount of Securities
    Beneficially Owned
    (Instr. 4)
    3.
    Ownership
    Form: Direct
    (D) or
    Indirect (I)
    (Instr. 5)
    4. Nature of Indirect Beneficial
    Ownership
    (Instr. 5)
    Common stock, par value of $.0001 (1) 27,756,668 I (1) By Managed Funds and Accounts

    Sentiment: Strong Buy

  • gadzillionman gadzillionman May 16, 2016 7:57 PM Flag

    Paulson bought 21m of the 30m share allotment , he already owned 9m shares so now his total is 27,756,668 shares ( to be exact ) his cost basis must be around $3.50. GADZ is long

    Sentiment: Strong Buy

  • What We Can Expect To See Moving Forward

    Moving forward, I have an overwhelmingly bullish opinion of what we can expect to see from SGYP. The reality is that there are few reasons to be bearish and plenty to be bullish. First and foremost, the concept of an acquisition seems to be a very likely one at this point, and if an acquisition does happen, you can expect a big premium. After all, with the Plecanatide NDA being accepted by the FDA, the valuation on the company is currently low. Talking about the Plecanatide NDA, I'm expecting that the FDA will approve the application. This will open the door for strong future profits. Finally, I'm incredibly impressed by the pipeline that Syngery Pharmaceuticals has created. For a clinical stage biotechnology company, their pipeline is one of the best. All in all, things seem to be looking great for SGYP.

    Sentiment: Buy

  • gadzillionman by gadzillionman May 14, 2016 8:24 PM Flag

    Hundreds of applications for these electronic birds will be in use around the world & a 127b business by 2020 several analyst has recently said so if GPRO can take just 10% share that would imply 12.7 B in sales . They will certainly come out with more products in the next few years & several projects are top secret unless someone hears any leaks ? I remember when AAPL was trading @ 7 & left for dead & FB was @ $18 yes, GPRO is down but not out ,Nick is doing the right things, but if sales remain sluggish too long I would look for AAPL or FB to buy them ? Long GPRO

    Sentiment: Buy

  • I guess they do not understand the path that IRWD has taken with similar drugs & flied through the FDA process, SGYP is going to piggyback those trials but do it much better, so where is the risk in terms of any FDA rejection ?? Cash is a bit concerning but they are addressing these issues very well, but if AGN comes in after the final IBS-C results sometime around Aug 2016, then SGYP & investors will have loads of cash & all the problems will go away, this company WILL be sold , so all the noise lack of money for product launch is a non issue, SGYP has said many, many times that they want to sell themselves & fortunately their is not a shortage of buyers. Long SGYP

    Sentiment: Buy

  • Reply to

    Why BO has stalled

    by gadzillionman May 12, 2016 8:37 AM
    gadzillionman gadzillionman May 12, 2016 11:48 AM Flag

    I'm a research scientist @ PACB, sorry didn't realize that this info would be considered insider information , I suppose if I was just a regular Joe investor doing research it wouldn't matter.

  • The big traders have been making millions in profits while the little guys have racked up millions in paper losses & real losses for those who cant hang on, they know their time is coming & when they have to buy back shares & hopefully @ much higher prices, LOL B@@strds when news came out of AGN preparing to make formal bid the short interest was reduced by 10m shares so we have real proof that some kind of deal is getting closer ..... Hang on Longs

    Sentiment: Buy

  • Reply to

    Why BO has stalled

    by gadzillionman May 12, 2016 8:37 AM
    gadzillionman gadzillionman May 12, 2016 9:10 AM Flag

    I doubt that could happen, because you would have an instant monopoly , I don't see much risk in the stock so happy just to hold , there must be @ least a $ 3-5 divergence with both sides not willing to talk anymore, it comes down to can PACB survive alone against a powerhouse like ILMN ? I'd say NO

  • gadzillionman by gadzillionman May 12, 2016 8:37 AM Flag

    PACB & Roche cannot agree on a price to get deal done , the average analyst has placed a value of $20 per share, so not sure how far apart they are ? sold half my position @ 10.24 so I'm happy either way, there could be other buyers interested but haven't read any articles on subject. PACB @ least is good to trade for daily & weekly profits!!

    Sentiment: Buy

  • gadzillionman by gadzillionman May 11, 2016 9:03 AM Flag

    ...in $3.6B Deal:...Allergan(AGN) Takeover of Synergy ...(NYSE:AGN is in advanced talks to acquire Synergy Pharmaceuticals (Nasdaq...

    Sentiment: Buy

  • gadzillionman gadzillionman May 11, 2016 7:39 AM Flag

    The AGN deal is already in the works , do some more research !! AGN will be receiving 33b in cash from Teva in June ,so even if product launches cost a 1b, they will certainly be able to pay the cost or more. AGN may sell their 50% stake after deal or just dominate the GI market, AGN wants SGYP & they can & will outbid all others. Smart money is on the long side , the news broke about AGN in talks with SGYP around the same time that short interest fell by 10m shares, institutional investors have been buying more shares like Paulson & JP Morgan plus many more so no logical bear case to made , but longs are smarter than you ,please keep that in mind before you waste your time posting #$%$!!

    Sentiment: Buy

  • SGYP 5/10/16 source: Nasdaq
    Settlement Date

    Short Interest

    Avg Daily Share Volume

    Days To Cover

    4/15/2016 17,333,427 3,635,354 4.768016
    3/31/2016 17,306,239 4,189,829 4.130536
    3/15/2016 27,282,159 2,016,319 13.530676
    2/29/2016 27,882,223 1,518,792 18.358158
    2/12/2016 28,077,534 1,956,089 14.353914
    1/29/2016 27,470,221 2,345,113 11.713815
    1/15/2016 27,720,760 3,679,906 7.533008
    12/31/2015 27,640,462 1,648,924 16.762726
    12/15/2015 28,666,708 1,349,576 21.241270
    11/30/2015 28,552,330 1,385,711 20.604823

    Sentiment: Buy

  • gadzillionman gadzillionman May 10, 2016 7:53 PM Flag

    Nobody cares about taking a dollar less for their shares , go peddle your #$%$ somewhere else !!! BO will happen via Allergan for @ least $ 15 but I see $ 17 as being their offer, do you really think investors just shelled out 89m for a $1 upside lol

    Sentiment: Buy

  • gadzillionman gadzillionman May 9, 2016 8:33 AM Flag

    Please don't post on YMB till that concussion from getting hit in the head with a golf ball goes away !! Allergan will be the buyer..... End of story

    Sentiment: Buy

  • 5 buyers & $25+ upside !!!! will take decent position on Mon. FYI: Take a look @ SGYP , a $3 stock with a BO price of $15+ with Allergan as the buyer, although it may be a few months away.... Long SGYP

    Sentiment: Buy

  • Thank You & Happy Hunting
    Bret Jensen

    Founder, Biotech Forum

    Disclosure: I am/we are long ACAD, AGN, AMGN, ANIP, BIIB, RLYP, SGYP.

    Sentiment: Buy

  • gadzillionman by gadzillionman May 6, 2016 9:30 AM Flag

    Synergy Pharma Seen 'Weighing' Options, Sell-Side Forecasts Upside Regardless Of M&A Rumors



    Benzinga News Desk , Benzinga Staff Writer

    Follow 
    May 05, 2016 12:29pm Comments


    Trade with confidence. Are you a professional trader? Be the first to get the alert with Benzinga Pro's real-time newsfeed and audio squawk and never miss an opportunity again.
    Don't miss the chance to try it FREE today.

    Synergy Pharma Seen 'Weighing' Options, Sell-Side Forecasts Upside Regardless Of M&A Rumors

    Related SGYP

    Jim Cramer Gives His Opinion On Synergy Pharmaceuticals And ABIOMED

    10 Stocks Moving In Monday's Pre-Market Session



    Like many small-cap biotech stocks, Synergy Pharmaceuticals Inc
    SGYP
    is no stranger to the rumor mill. StreetInsider reported the company was exploring a sale on April 8, sending shares 8 percent higher.

    Bloomberg reported a similar rumor in March 2015, also yielding no follow-through.

    Little has happened on the M&A front since that report. News that Synergy's new drug application (NDA) for Plecanatide had been accepted by the FDA on April 19 pushed the stock up another 11 percent, leading analysts at Rodman & Renshaw and Roth Capital to reiterate bullish theses the next day.

    The NDA is now under review with a target PDUFA action date of January 29, 2017.

    Synergy Management Seen 'Weighing' Options

    So, if Synergy buyout chatter emerges again, should investors take it seriously? It depends on the timeline

    Roth's Michael Higgins told Benzinga this week that as far as he could tell, the company has not put itself on the block at the moment. However, he didn't rule it out over the long-term.

    Management, he said, is "weighing their options, doing what most companies do in their position: consider the market oppo

    Sentiment: Buy

  • Another possible acquisition target would be New York-based Synergy Pharmaceuticals. Today Synergy announced that the U.S. Food and Drug Administration (FDA) had given a PDUFA target of Jan. 29, 2017 for plecanatide, the company’s first uroguanylin analog for the treatment of chronic idiopathic constipation (CIC).

    Jensen notes that Synergy’s drug appears to be better than the current market leader, Ironwood Pharmaceuticals (IRWD)’ Linzess, which makes about $450 million in annual sales, but projects to be able to hit $1 billion by 2020. Synergy has an enterprise value of about $400 million.

    And others have offered up Cambridge, Mass.-based Biogen (BIIB) as a potential target, as well as North Chicago, Ill.-based AbbVie (ABBV), Celgene (CELG), Bristol-Myers Squibb (BMY) or AstraZeneca (AZN).

    If Allergan opted for smaller buys in the dermatology market, it might consider Revance Therapeutics (RVNC), Anacor Pharma (ANAC) or Dermira.

    Sentiment: Buy

  • Reply to

    Allergan bidding 3.6B

    by gadzillionman May 3, 2016 10:10 AM
    gadzillionman gadzillionman May 3, 2016 6:37 PM Flag

    It's called research , the info I found cannot be copied & pasted to this message board , but with 180m shares in all, that would imply about a $20 buyout , so that would be a reasonable amount & Allergan will have about 33B soon, so money wont be an issue, they want SGYP bad !!! Gadz is long SGYP of course & no need to pump anything , I plan on making lots of profit very soon.

    Sentiment: Strong Buy

  • gadzillionman by gadzillionman May 3, 2016 10:10 AM Flag

    Lets see if Gadz is right ?

    Sentiment: Strong Buy

ILMN
143.85+0.73(+0.51%)May 27 4:00 PMEDT